News
Trevi Therapeutics to Present Phase 2 Results of Haduvio for Chronic Cough at ATS 2024 Conference
9 Apr 24
News
Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target
9 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Oppenheimer Maintains Outperform on Trevi Therapeutics, Maintains $9 Price Target
21 Mar 24
News, Price Target, Analyst Ratings
Trevi Therapeutics: Q4 Earnings Insights
20 Mar 24
Earnings
Trevi Therapeutics Q4 2023 GAAP EPS $(0.08) Beats $(0.09) Estimate
20 Mar 24
Earnings, Earnings Beats, News
Earnings Scheduled For March 20, 2024
20 Mar 24
Earnings
Earnings Outlook For Trevi Therapeutics
19 Mar 24
Earnings
Press releases
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
9 Apr 24
Press Releases
Trevi Therapeutics to Participate in Upcoming April Events
4 Apr 24
Press Releases
Trevi Therapeutics to Participate in Upcoming April Events
4 Apr 24
Press Releases
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
2 Apr 24
Press Releases
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
20 Mar 24
Earnings, Press Releases
Trevi Therapeutics to Participate in Upcoming March Events
28 Feb 24
Press Releases
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
6 Feb 24
Press Releases